After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. | In this ...

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill Nereus. The decision came 15 months after the ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house executive to lead the surge. | Suarez will return to the U.S. as SVP and ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter’s operations around ...

Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at ...

The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...

Viking has identified Neil Aubuchon as the person to oversee its commercial preparations. Aubuchon has joined the biotech as ...